miR-92b-3p-TSC1 axis is critical for mTOR signaling-mediated vascular smooth muscle cell proliferation induced by hypoxia

Jihui Lee1 · Jeongyeon Heo1 · Hara Kang1

Received: 29 November 2017 / Revised: 11 November 2018 / Accepted: 15 November 2018 / Published online: 5 December 2018
© The Author(s) 2018. This article is published with open access

Abstract
Pulmonary artery smooth muscle cells (PASMCs) undergo proliferation by the mammalian target of rapamycin (mTOR) signaling pathway under hypoxia. Hypoxia induces expression of a specific set of microRNAs (miRNAs) in a variety of cell types. We integrated genomic analyses of both small non-coding RNA and coding transcripts using next-generation sequencing (NGS)-based RNA sequencing with the molecular mechanism of the mTOR signaling pathway in hypoxic PASMCs. These analyses revealed hypoxia-induced miR-92b-3p as a potent regulator of the mTOR signaling pathway. We demonstrated that miR-92b-3p directly targets the 3′-UTR of a negative regulator in the mTOR signaling pathway, TSC1. mTOR signaling and consequent cell proliferation were promoted by enforced expression of miR-92b-3p but inhibited by knocking down endogenous miR-92b-3p. Furthermore, inhibition of miR-92b-3p attenuated hypoxia-induced proliferation of vascular smooth muscle cells (VSMCs). Therefore, this study elucidates a novel role of miR-92b-3p as a hypoxamir in the regulation of the mTOR signaling pathway and the pathological VSMC proliferative response under hypoxia. These findings will help us better understand the miRNA-mediated molecular mechanism of the proliferative response of hypoxic VSMCs through the mTOR signaling pathway.

Introduction
Hypoxia contributes to the pathogenesis of various human diseases, including cancer, stroke and pulmonary artery hypertension [1, 2]. Hypoxia stimulates abnormal proliferation and migration of vascular smooth muscle cells (VSMCs), resulting in decreased luminal diameter and obstruction of pulmonary arteries [3]. Although the molecular mechanisms involved in the proliferative and migratory responses are still not completely understood, it has been shown that chronic hypoxia-induced proliferation requires activation of the mTOR signaling pathway [4]. The potential importance of the mTOR signaling pathway for regulating proliferation and survival of VSMCs and in development of vascular remodeling in pulmonary hypertension has been suggested [5].

mTOR is a well-conserved serine/threonine kinase that plays a central role in the signaling network controlling cell proliferation, growth, survival and metabolism in response to various environmental cues [6]. mTOR belongs to the phosphoinositide 3-kinase (PI3K)-related kinase family and interacts with several proteins to form two distinct complexes named mTOR complex 1 (mTORC1) and 2 (mTORC2). mTORC1 regulates cell growth through S6K1 and 4E-BP1 in response to nutrients and growth factors. A heterodimer consisting of tuberous sclerosis 1 (TSC1) and TSC2 is a key upstream regulator of mTORC1 and functions as a GTPase-activating protein (GAP) for the Ras homolog enriched in brain (RHEB) GTPase. GTP-bound RHEB interacts with mTORC1 and activates the mTOR signaling pathway. As a RHEB GAP, TSC1/2 negatively regulates the mTOR signaling pathway.

Hypoxia regulates gene expression through a transcription factor, hypoxia-inducible factor-1 (HIF-1), which orchestrates the transcriptional regulation of a variety of genes such as vascular endothelial growth factor (VEGF)
Hypoxia also regulates the expression of a specific group of miRNAs, termed hypoxamiRs, through transcriptional and non-transcriptional mechanisms. The master hypoxamiR, miR-210, is upregulated at the transcriptional level by HIF-1 in a variety of cell types in response to hypoxia [8]. Upregulation of miR-210 has been detected especially in cardiovascular diseases and solid tumors [9]. In addition to transcriptional regulation of miRNAs, hypoxia can regulate miRNA levels through post-translational modification of a component of the RNA-induced silencing complex, Argonaute2 (Ago2), independently of HIF-1. Hypoxia induces prolyl-hydroxylation and accumulation of Ago2, leading to increased expression levels of miRNAs such as miR-451 [10].

There is growing evidence that miRNAs play important roles in cellular responses to hypoxia and in pulmonary hypertensive vascular remodeling [11–14]. Furthermore, several miRNAs that regulate the mTOR signaling pathway have been identified in various cell types. For example, miR-96 and miR-199a-3p target mTOR in prostate cancer cells and hepatocellular carcinoma, respectively [15, 16]. miR-155 also regulates the mTOR signaling pathway by suppressing multiple targets such as RHEB and Rictor [17]. Therefore, we hypothesized that hypoxia modulates miRNA expression to activate the mTOR signaling pathway, leading to a pathological VSMC proliferative response.

Here, we present the miRNA expression profile of hypoxia-induced pulmonary artery smooth muscle cells (PASMCs) in comparison with that of normoxia cells by NGS-based small RNA sequencing. We observed unique miRNA expression signatures that could be regulators under low oxygen stress. We provide evidence for a major contribution of miR-92b-3p to the regulation of the hypoxia-mediated mTOR signaling pathway and identify TSC1 as a direct target of miR-92b-3p. Our finding of the miR-92b-3p-TSC1 axis, specifically induced by hypoxia, will help us better understand the molecular mechanism of the proliferative response of VSMCs through the mTOR signaling pathway. Furthermore, the importance of miR-92b-3p modulation to mTOR signaling-mediated cellular responses will provide invaluable insight for therapeutic approaches to abnormal VSMC proliferation, triggering vascular remodeling in hypoxia-induced pulmonary hypertension.

**Results**

**Hypoxia induces mTOR signaling pathway and promotes proliferation of vascular smooth muscle cells**

To ascertain the effect of hypoxia on VSMCs, PASMCs exposed to normoxia or hypoxia for 24 h were prepared. We first examined the expression levels of genes known to be regulated by hypoxia, including VEGF, glucose transporter 1 (GLUT-1), and type I collagen prolyl-4-hydroxylase (C-P4H(I)) as well as miR-210 by qRT-PCR. The levels of all three gene transcripts and of mature miR-210 in PASMCs were increased by hypoxia (Fig. 1a). The protein level of HIF1α, a key transcription factor under hypoxic conditions, was then examined by immunoblotting. As expected, significant induction of HIF1α upon hypoxia was confirmed (Fig. 1b).

While hypoxia inhibits the mTOR signaling pathway in the majority of cells, mTOR signaling is known to be activated in the hypoxia-mediated VSMC proliferation phenotype [4]. To demonstrate that hypoxia mediates activation of the mTOR signaling pathway in PASMCs, we examined the phosphorylation of S6K1 (Thr389) in hypoxia-exposed PASMCs. The phosphorylation of S6K1 at threonine 389 (pS6K1) has been used as a hallmark of mTOR signaling pathway activation. Consistent with the results of previous studies [4], the phosphorylation of S6K1 (Thr389) was significantly increased by hypoxia (Fig. 1c).

Next, cell proliferation was examined. PASMCs exposed to normoxia or hypoxia were stained with an antibody against Ki-67 to measure the number of proliferating cells under each condition. Hoechst dye was used for nuclear staining. Approximately 9% of cells are Ki-67-positive under normoxia, and the percentage of Ki-67-positive cells increased to approximately 25% under hypoxia. Quantitative analysis of Ki-67 staining indicates that hypoxia increases the number of proliferating cells approximately 2.8-fold compared with normoxia control (Fig. 1d).

**Hypoxia regulates TSC1, a negative regulator of mTOR signaling**

To understand the underlying molecular events leading to mTOR signaling pathway activation in response to hypoxia, we investigated the global mRNA profiles of PASMCs (normoxia) and their changes under hypoxia using NGS-based RNA sequencing (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118363). Library of RNA sequencing was made of total RNA from 6 x 10⁵ PASMCs and one sample per each condition was sequenced. From the RNA sequencing data, 302 genes were upregulated and 167 genes were downregulated upon hypoxia when differentially expressed genes (DEG) were adjusted to |fold change| ≥ 2 (Supplementary data 1). KEGG pathway analysis for the DEG showed that genes involved in metabolic pathways were enriched. Clustered heatmap of KEGG pathway enrichment analysis is shown in Supplementary data 2.

Among known key components of the mTOR signaling pathway such as mTOR, TSC1, TSC2 and RHEB, we observed that the relative expression level of TSC1 was...
significantly reduced to 68% in hypoxia-exposed PASMCs (Fig. 2a). No other genes investigated showed significant changes in hypoxic conditions. TSC1 mRNA levels were examined after exposure of hypoxia by qRT-PCR (Fig. 2b). The level of TSC1 transcripts was significantly reduced to 38% after 24 h of hypoxia in accordance with the RNA sequencing data, but the transcript level did not change after 8 h of hypoxia, suggesting that the down-regulation of TSC1 by hypoxia is likely through post-transcriptional regulation. To test this possibility, PASMCs were treated with the RNA polymerase II inhibitor actinomycin D (ActD) prior to hypoxia exposure, followed by qRT-PCR analyses of TSC1 transcripts (Fig. 2c). After actinomycin D treatment to block new transcription, the amount of TSC1 transcripts was significantly reduced. TSC1 mRNA levels in cells exposed to hypoxia for 8 h did not change compared to normoxia in both presence and absence of actinomycin D. In contrast, the TSC1 transcript level was reduced by hypoxia exposure for 24 h and this downregulation occurred whether or not actinomycin D was added, indicating that existing TSC1 transcripts was downregulated by hypoxia. Therefore, this downregulation of TSC1 is likely to occur at the post-transcriptional level. The significant reduction of TSC1 protein levels by
Hypoxia was validated by immunoblotting (Fig. 2d). TSC1 is known to inhibit the mTOR signaling pathway in complex with TSC2. Therefore, these results suggest that the mTOR signaling pathway is activated upon hypoxia by downregulation of TSC1, a negative regulator of the mTOR signaling pathway.

**TSC1 regulates the proliferation of VSMCs through the mTOR signaling pathway**

Next, we confirmed that TSC1 affects the proliferation of PASMCs by regulating mTOR signaling. First, the effects of TSC1 on mTOR signaling activation in PASMCs were examined by downregulating TSC1 using siRNA (Fig. 3a). When TSC1 mRNA and protein levels were downregulated by siRNAs by approximately 80 and 50%, respectively, the phosphorylation of S6K1 (Thr389) increased by approximately 1.5-fold compared with control. This suggests that TSC1 plays a role as a negative regulator of mTOR signaling in PASMCs, as expected. We then examined whether cell proliferation was affected by the downregulation of TSC1. PASMCs transfected with siRNA against TSC1 were stained with a Ki-67 antibody to measure the number of proliferating cells (Fig. 3b). The percentage of Ki-67-positive cells increased approximately 2-fold when TSC1 was downregulated, suggesting that the downregulation of TSC1 is sufficient to promote the proliferation of PASMCs.

All of these results indicate that the proliferation of VSMCs is regulated by modulating TSC1, a negative regulator in mTOR signaling.

**miRNA levels are regulated by hypoxia**

Generally, miRNAs play a role in the negative post-transcriptional regulation of target genes. Multiple miRNAs have been proposed as important mediators modulating the VSMC phenotype [18, 19]. In addition, growing evidence suggests that a subset of miRNAs is up- or downregulated by hypoxia, and it was named "hypoxamirs" [20, 21]. Thus, we hypothesized that miRNAs modulated by hypoxia in VSMCs downregulate TSC1 post-transcriptionally by targeting TSC1 mRNA, leading to the activation of mTOR signaling. To search for miRNAs regulated by hypoxia in VSMCs, comprehensive miRNA profiles from PASMCs under normoxia and hypoxia were obtained by NGS-based small RNA sequencing (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118363). Library of small RNA sequencing was made of total RNA from 6 × 10⁵ PASMCs and one sample per condition was sequenced. We identified 23 miRNAs upregulated ≥ 1.5-fold in hypoxia-exposed PASMCs in comparison to those cells exposed to normoxia. The expression level of the master hypoxamir, miR-210, increased by approximately 3-fold in hypoxia-exposed PASMCs consistently with previous studies [22]. We also...
identified eight miRNAs whose expression is reduced to less than 50% under hypoxia (Table 1).

**miR-92b-3p is upregulated by hypoxia**

To investigate a possible interaction between miRNA and TSC1, we searched for potential miRNA recognition elements (MREs) of 23 miRNAs upregulated by hypoxia within the 3′-UTR of TSC1 gene using the TargetScan target prediction algorithm and the miRWalk database. We observed an evolutionarily conserved MRE partially complementary to miR-92b-3p in the 3′-UTR of the TSC1 gene (Fig. 4a). It suggests that miR-92b-3p might mediate reduced expression of TSC1 by direct targeting. Before testing whether miR-92b-3p targets TSC1, we validated the hypoxia-mediated induction of mature miR-92b-3p expression level by qRT-PCR (Fig. 4b). The expression of mature miR-92b-3p was all increased by hypoxia at the 24 h time point, but only pri-miR-92b-3p expression was induced by hypoxia at the 8 h time point, suggesting that miR-92b-3p is likely to be transcriptionally induced by hypoxia.

**TSC1 is a direct target of miR-92b-3p**

To determine whether miR-92b-3p targets TSC1 by direct binding, we measured the expression of a luciferase reporter construct containing the 3′-UTR of TSC1 3′-UTR (4884 bp) was predicted by computer algorithms, the **TSC1 3′-UTR construct was generated with a part of TSC1 3′-UTR (935 bp) including the predicted MRE downstream of the luciferase reporter gene (Fig. 5a). The luciferase activity of the 3′-UTR construct was significantly reduced upon overexpression of the miR-92b-3p mimic, but not that of the 3′-UTR mutant construct which is the same construct with a mutated MRE region (Fig. 5b). This suggests that miR-92b-3p suppresses TSC1 expression by targeting the MRE within the 3′-UTR. To further support this notion that miR-92b-3p targets TSC1 through the evolutionarily conserved MRE in the 3′-UTR of the TSC1 gene, a luciferase
reporter construct containing the sequence of 23-bp MRE (MRE construct) was generated (Fig. 5a). miR-92b-3p reduced the luciferase activity of the MRE construct by approximately 60%. Mutations in the MRE construct (MRE mt), which disrupted base pairing with miR-92b-3p, abrogated the inhibition of luciferase activity by miR-92b-3p, suggesting that the conserved MRE is a critical target site for recognition of TSC1 mRNA by miR-92b-3p (Fig. 5b).

We investigated whether endogenous TSC1 mRNA levels were modulated by miR-92b-3p in PASMCs. The level of TSC1 mRNA relative to 18S rRNA is reduced to approximately 50% in miR-92b-3p mimic-transfected PASMCs compared with the control miRNA-transfected PASMCs, indicating that miR-92b-3p downregulates TSC1 expression (Fig. 5c). Conversely, when miR-92b-3p was inhibited by the transfection of miR-92b-3p antisense inhibitor RNA (anti-miR-92b-3p) in PASMCs, TSC1 expression increased approximately 2.5-fold, indicating that the endogenous miR-92b-3p represses TSC1 expression. Moreover, immunoblot analyses indicated that the endogenous TSC protein level in PASMCs was reduced by exogenous miR-92b-3p mimic, but the basal level of TSC1 protein was elevated by anti-miR-92b-3p in comparison with control (Fig. 5d). All of these results demonstrate that TSC1 is a novel target of miR-92b-3p. To confirm overexpression and downregulation of miR-92b-3p, the level of miR-92b-3p was measured in PASMCs at 24 h after transfection with miR-92b-3p mimic or anti-miR-92b-3p (Fig. 5e).

| miRNA         | Fold change (Hypoxia/Normoxia) |
|---------------|-------------------------------|
| hsa-miR-210-3p| 3.69                          |
| hsa-miR-210-5p| 3.20                          |
| hsa-miR-1260a | 2.54                          |
| hsa-miR-1260b | 2.54                          |
| hsa-miR-665   | 2.30                          |
| hsa-miR-1268a | 2.16                          |
| hsa-miR-1268b | 2.11                          |
| hsa-miR-5701  | 1.84                          |
| hsa-miR-33b-5p| 1.77                          |
| hsa-miR-654-3p| 1.70                          |
| hsa-miR-21-3p | 1.63                          |
| hsa-miR-126-5p| 1.63                          |
| hsa-miR-874-3p| 1.59                          |
| hsa-miR-1185-2-3p| 1.57                         |
| hsa-miR-431-5p | 1.56                         |
| hsa-miR-485-3p | 1.56                         |
| hsa-miR-378c  | 1.55                          |
| hsa-miR-1271-5p| 1.55                         |
| hsa-miR-212-3p| 1.52                          |
| hsa-miR-337-5p| 1.52                          |
| hsa-miR-410-3p| 1.51                          |
| hsa-miR-92b-3p| 1.50                          |
| hsa-miR-766-3p| 1.50                          |
| hsa-miR-3179  | -11.54                        |
| hsa-miR-184   | -7.70                         |
| hsa-miR-6859  | -3.55                         |
| hsa-miR-19b-3p| -2.36                         |
| hsa-miR-19a-3p| -2.26                         |
| hsa-miR-1302  | -2.25                         |
| hsa-miR-6511a | -2.16                         |
| hsa-miR-186-3p| -2.12                         |

Fig. 4 Hypoxia regulates the expression level of miR-92b-3p. a The miR-92b-3p MRE sequence found in the 3′-UTR of TSC1 mRNA is evolutionarily conserved. Hsa: human, Mmu: mouse, Rno: rat, Ssc: pig. b Expression levels of miR-92b-3p normalized to U6 snRNA were examined by qRT-PCR in PASMCs exposed to normoxia or hypoxia for 24 h. *p < 0.05. c pri- and pre-miR-92b-3p levels relative to 18S rRNA and mature miR-92b-3p levels relative to U6 snRNA were measured by qRT-PCR at 8 h and 24 h after exposure to hypoxia. Data represent fold change of the RNA levels in hypoxia-exposed PASMCs from normoxia control cells. *p < 0.05.
miR-92b-3p-mediated downregulation of TSC1 is essential for the activation of mTOR signaling upon hypoxia

To investigate the significance of miR-92b-3p-mediated downregulation of TSC1 on hypoxia-induced mTOR signaling activation, we examined whether mTOR signaling activation upon hypoxia is reversed by miR-92b-3p-refractory TSC1. We overexpressed exogenous TSCI mRNAs, which have deleted 3′-UTR and are resistant to miR-92b-3p, in PASMCs using Nucleofector (Lonza) and examined the changes in mTOR signaling activation under hypoxia by western blotting of phosphorylated S6K1 (Thr389) (Fig. 6). The TSC1-expressing vector containing the miR-92b-3p binding site within 3′-UTR was used as a control. Hypoxia-induced phosphorylation of S6K1 (Thr389) was significantly impaired when the exogenous 3′-UTR-deleted TSCI mRNAs (TSCI\textsuperscript{\textit{wo}3′-UTR}) are

**Fig. 5** TSC1 is a target of miR-92b-3p. \textbf{a} (Left panel) Schematic diagram of predicted miR-92b-3p MRE in the 3′-UTR of TSC1 transcripts and luciferase reporter constructs used for luciferase assays. CDS and AAA stand for protein coding sequence and poly(A) tail, respectively. Mutations introduced in the MRE to disrupt a base paring with miR-92b-3p sequence are indicated as black circles. (Right panel) Sequences of the 3′-UTR, the 3′-UTR mt, the wild-type miR-92b-3p MRE in the 3′-UTR of TSC1 (MRE) and the MRE mt cloned into the 3′-UTR of the luciferase gene are shown. The mutated sequence is in bold. Perfect base matches are indicated by a line. \textbf{b} Luciferase activity of constructs, such as the 3′-UTR, the 3′-UTR mt, the MRE and MRE mt, were examined in Cos7 cells by transfecting control or miR-92b-3p mimic. A luciferase vector without 3′-UTR sequence (Vector) was used as a negative control. Data represent the mean ± S.E. of triplicates. \textbf{c} Levels of endogenous TSCI mRNA relative to 18S rRNA were quantified by qRT-PCR analysis in PASMCs transfected with control mimic, miR-92b-3p mimic, or anti-miR-92b-3p. Data represent the mean ± S.E. of triplicates. \textbf{d} Immunoblot analysis of TSCI and β-actin using cell lysates of PASMCs transfected with control mimic, miR-92b-3p mimic or anti-miR-92b-3p were performed. Protein bands were quantitated by densitometry, and relative amounts of protein normalized to β-actin are presented. \textbf{e} Levels of endogenous miR-92b-3p relative to U6 snRNA were quantified by qRT-PCR analysis in PASMCs transfected with control mimic, miR-92b-3p mimic, or anti-miR-92b-3p. Data represent the mean ± S.E. of triplicates. *p < 0.05
overexpressed, suggesting that miR-92b-3p-mediated downregulation of TSC1 is essential for the activation of mTOR signaling upon hypoxia.

miR-92b-3p is responsible for the mTOR signaling pathway activation and VSMC proliferation

To further support that miR-92b-3p regulates the mTOR signaling pathway by targeting TSC1 in VSMCs, we investigated the role of miR-92b-3p in regulation of the mTOR signaling pathway. PASMCs were transfected with miR-92b-3p mimic or anti-miR-92b-3p and subjected to immunoblot analysis using an antibody against phosphorylated S6K1 (Thr389) to examine activation of the mTOR signaling pathway. When miR-92b-3p was overexpressed in PASMCs, phosphorylation of S6K1 (Thr389) was induced (Fig. 7a). In contrast, anti-miR-92b-3p impaired the phosphorylation of S6K1 (Thr389) in PASMCs (Fig. 7b). These results suggest that miR-92b-3p acts as a positive regulator of the mTOR signaling pathway.

Next, the role of miR-92b-3p in the proliferation of VSMCs was examined (Fig. 7c). PASMCs transfected with control mimic, miR-92b-3p mimic or anti-miR-92b-3p were stained with an antibody against Ki-67. The percentage of proliferating cells was increased by hypoxia approximately 2-fold in comparison with control. On the other hand, cells transfected with anti-miR-92b-3p showed significantly reduced numbers of Ki-67-positive proliferating cells by 50% in comparison with control. These results demonstrate that induction of miR-92b-3p is required for promoting the proliferation of VSMCs. Therefore, it is likely that miR-92b-3p induced by hypoxia promotes VSMC proliferation through activation of the mTOR signaling pathway by suppressing TSC1.

Modulation of miR-92b-3p controls mTOR signaling-mediated VSMC proliferation induced by hypoxia

Since hypoxia-induced miR-92b-3p activates the mTOR signaling pathway, we examined whether modulation of miR-92b-3p using anti-miR-92b-3p affects the hypoxia-mediated mTOR signaling activation (Fig. 8a). PASMCs transfected with control or anti-miR-92b-3p for 24 h were exposed to normoxia or hypoxia for 24 h. In control-transfected PASMCs, hypoxia accelerates the phosphorylation of S6K1 (Thr389) consistent with previous data (Fig. 1c). However, the hypoxia-induced phosphorylation of S6K1 (Thr389) was impaired when miR-92b-3p was downregulated by anti-miR-92b-3p, suggesting that modulation of miR-92b-3p controls the mTOR signaling pathway activation by hypoxia.

Next, we determined whether modulation of miR-92b-3p influences hypoxia-induced VSMC proliferation (Fig. 8b). PASMCs transfected with control mimic, miR-92b-3p or anti-miR-92b-3p were stained with an antibody against Ki-67. The percentage of proliferating cells was increased by hypoxia approximately 2-fold in comparison with control. However, when PASMCs were transfected with anti-miR-92b-3p prior to hypoxia exposure, the number of proliferating cells was significantly reduced to the level of control mimic-transfected normoxia cells. It suggests that downregulation of miR-92b-3p inhibits hypoxia-induced VSMC proliferation. Together, all the data suggest that modulation of miR-92b-3p controls mTOR signaling-mediated VSMC proliferation induced by hypoxia.

Discussion

Hypoxia causes vasoconstriction of the pulmonary vasculature in concert with vascular remodeling leading to
pulmonary hypertension [23]. Under hypoxia conditions, the proliferation of VSMCs is enhanced and activation of the mTOR signaling pathway is involved. Recent studies strongly suggest that miRNAs act as critical mediators of the hypoxic response [20, 21]. We thus hypothesized their prominent role in hypoxia-exposed VSMCs and aimed to characterize the overall miRNA expression profile in VSMCs by an NGS-based approach to identify hypoxia-modulated miRNAs. Twenty-three upregulated miRNAs were identified in hypoxia-exposed VSMCs compared with normoxia controls. Among the most significant changes observed in miRNAs with potential relevance to the mTOR signaling pathway was elevated miR-92b-3p. We demonstrated that hypoxia-induced miR-92b-3p targets a negative regulator in the mTOR signaling pathway, TSC1. Regulation of the miR-92b-3p-TSC1 axis is critical for hypoxia-induced proliferation of VSMCs. Inactivation of miR-92b-3p using an antisense inhibitor RNA reverses hypoxia-induced activation of the mTOR signaling pathway and cell proliferation.

miR-92b-3p has been reported to be involved in cell proliferation [24, 25]. For example, miR-92b-3p is enriched in human embryonic stem cells and controls their proliferation [26]. Moreover, miR-92b-3p has been shown to be upregulated in many types of human cancer and to promote cell proliferation and metastasis. Disabled homolog 2-interacting protein (DAB2IP), Smad7, reversion inducing cysteine rich protein with Kazal motifs (RECK), Dkkopf-3 (Dkk3) and Smad3 have been identified as targets of miR-92b-3p and responsible for the promotion of cell proliferation and invasion in bladder cancer, hepatocellular carcinoma, osteosarcoma, glioma and glioblastoma, respectively [24, 25, 27–29]. However, these known target mRNAs were not downregulated in hypoxia-exposed VSMCs from our NGS-based RNA sequencing data (Table 2), suggesting that hypoxia-induced miR-92b-3p
regulates the proliferation of VSMCs by targeting unknown novel targets. We identified a negative regulator in the mTOR signaling pathway, TSC1, as a novel target of miR-92b-3p in VSMCs. Upon hypoxia, TSC1 is suppressed by miR-92b-3p, which might inhibit TSC1/2 complex formation and lead to mTORC1 activation, resulting in mTOR signaling pathway activation and consequent increase in VSMC proliferation.

Regulation of the mTOR signaling pathway by miRNAs has been studied. Especially, a number of miRNAs have been identified to directly target components of the mTOR signaling pathway, because deregulation of multiple elements of the mTOR signaling pathway has been reported in many types of cancers. For example, miR-99a, miR-99b, miR-100, miR-199a-3p, miR-224, miR-101-2, miR-544, miR-144-3p, miR-520c and miR-373 have been shown to target mTOR in colorectal cancer, lung cancer, cervical cancer, gastric cancer, breast cancer, hepatocellular carcinoma, salivary adenoid carcinoma, and fibrosarcoma cells. In addition, Rictor, a key component of the mTOR complex, has been reported as a target of miR-142-3p and miR-218 in lymphoma and oral cancer cells. However, the biological role of miR-92b-3p has not yet been reported in the context of mTOR signaling pathway regulation. In this study, we demonstrated a link between miR-92b-3p and the mTOR signaling pathway.

To date, miR-100 and miR-761 have been illustrated to have the role of an mTOR modulator in the regulation of vascular cell proliferation. An miRNA transcriptome analysis of hind-limb ischemia-induced mice demonstrated that miR-100 is downregulated after induction of ischemia. Potential target genes downregulated by miR-100 overexpression were screened for miRNA recognition elements in the 3′-UTR, and mTOR was identified as an miR-100 target gene in endothelial cells. More recently, miR-761 was identified as an mTOR targeting miRNA by screening potential miRNAs that target mTOR using a computer prediction algorithm, TargetScan. miR-761 repressed mTOR expression and consequently suppressed VSMC proliferation. Indeed, miR-761 is downregulated during angiotensin II-induced proliferation of VSMCs.

### Table 2 Expression levels of known target mRNAs of miR-92b-3p from NGS analysis

| Gene   | Fold change (Hypoxia/Normoxia) |
|--------|--------------------------------|
| DAB2IP | 1.04                           |
| Smad7  | 1.28                           |
| RECK   | 1.17                           |
| DKK3   | 1.16                           |
| Smad3  | -1.07                          |
examined whether these miRNAs are downregulated in hypoxia-exposed PASMCs. From our NGS-based small RNA sequencing data, the level of miR-100 expression was not changed in response to hypoxia, and the expression of miR-761 was not determined. It suggests that it is unlikely that miR-100 and miR-761 are responsible for the mTOR signaling-mediated promotion of VSMC proliferation under hypoxia. We identified miR-92b-3p as a novel hypoxamir, and observed its role in the mTOR signaling-mediated proliferative response of hypoxic VSMCs.

Because the mTOR signaling pathway is involved in the increase of VSMC proliferation, which is a major pathological phenotype in hypoxia-induced vascular proliferative diseases, the mTOR signaling pathway could be considered a target for the treatment of vascular diseases including pulmonary artery hypertension. In this study, hypoxia-induced activation of the mTOR signaling pathway and proliferation in VSMCs are reversed by downregulation of miR-92b-3p using an antisense inhibitor RNA. This result suggests not only a molecular mechanism of miRNA-mediated mTOR signaling pathway regulation in hypoxia-induced VSMC pathogenesis but also a potential therapeutic strategy to effectively control development of vascular diseases.

**Materials and methods**

**Cell culture and hypoxia**

Human primary pulmonary artery smooth muscle cells (PASMCs) were purchased from Lonza (CC-2581) and were maintained in Sm-GM2 medium (Lonza) containing 5% fetal bovine serum (FBS). For hypoxia, the cells were placed in fresh medium and incubated in a sealed modular incubator chamber (Billups-rothenberg inc.) for 24 h at 37°C after flushing with a mixture of 5% CO₂, 1% O₂ and 94% N₂ for 4 min.

**Quantitative reverse transcriptase-PCR (qRT-PCR)**

Quantitative analysis of the change in expression levels was performed using real-time PCR. The mRNA levels were normalized to 18S rRNA. The primers used were as follows: TSC1, 5′-CTCCACAGCAGATGACATA-3′ and 5′-GCTGCCGTTCCAAGAACTC-3′; VEGF, 5′-AAGGAGGGCAAAATCAT-3′ and 5′-ATCTGGATGTGGTATGGTGA-3′; GLUT-1, 5′-CTTCACTGTCGTGTCGCTG-3′ and 5′-CCAGGACCACACTTCAGGAGG-3′; C-P4H(1), 5′-AAGGCGAGATTGTACCATC-3′ and 5′-TTGGTCTAGCTGGAAGCAGACT-3′; 18S rRNA, 5′-GTAACCGTTGAACCCCATCT-3′ and 5′-CCATCAAATCGGTTAGTACC-3′; pri-miR-92b-3p, 5′-CGGCGGATCTTTGTAATGATGTTA-3′. For quantification of mature miRNAs such as miR-92b-3p and miR-210, and pre-miR-92b-3p, the miScript PCR assay kit (Qiagen) and miScript precursor assay kit (Qiagen) were used, respectively, according to the manufacturer's instructions. Data analysis was performed using a comparative C₂ method in the Bio-Rad software. miRNA levels were normalized to U6 small nuclear RNA. Three experiments were performed in triplicate, and the average results with standard errors are presented.

**miRNA mimics and anti-miRNA oligonucleotides**

Chemically modified double-stranded RNAs designed to mimic the endogenous mature miR-92b-3p, miR-92b-3p antisense inhibitor RNA (anti-miR-92b-3p) and negative control miRNA were purchased from Genolution Pharmaceuticals. The miRNA mimics and anti-miRNA oligonucleotides were transfected at 5 nM and 50 nM, respectively, using RNAi Max (Invitrogen) according to the manufacturer's protocol.

**RNA interference**

Small interfering RNA (siRNA) duplexes were synthesized by Genolution Pharmaceuticals. The target nucleotide sequence for TSC1 siRNA (5′-UAUUUAACACAAUCGCCGUU-3′) was used. Negative control siRNA (Qiagen) was used as a control.

**Luciferase reporter constructs**

A part of the 3′-UTR sequence of TSC1 (935 bp) including the predicted miRNA recognition element (MRE) was cloned into the pS0 vector (Addgene) containing the luciferase gene (3′-UTR). RT-PCR was used to amplify the 3′-UTR sequence of TSC1 from mRNA isolated from PASMCs using 5′-ATGGAGCTCTGTTTGGAATGG ACGGAG-3′ and 5′-ATGGGCCCGCCCGGGAAATGTG GGTCGA-3′. For the 3′-UTR mt, which is the same 3′-UTR with a mutated MRE sequence, an upstream region and a downstream region of the MRE site in the 3′-UTR construct were amplified using primers including the XhoI enzyme recognition sequences. Two PCR products were digested by XhoI enzyme, ligated to change the MRE sequence into the XhoI recognition sequence and then cloned into the pS0 vector. 5′-ATGGAGCTCTGTTTGGAATGGGAC CGGAG-3′ and 5′-TCACTCGAGCGGTTCAGGAGG GCAAC-3′ were used for the amplification of the upstream region. 5′-TCACTCGAGATGCCAAATTATTTATTTG TG-3′ and 5′-ATGGGCCCGGCCTGGAAATGTGGT CA-3′ were used for the amplification of the downstream region. The predicted MRE sequence (23 bp) and MRE mutant (MRE mt) sequence were cloned into the pS0

**Springer Nature**
vector (Addgene). 5′-GGGCTCCCTTGAACCTGTGGAAT ACCGG-3′ and 5′-TATGGCACAGGTCAAAAGGACGC AGCT-3′ were used for the MRE and 5′-GGGCTCCCTT GAAACCTGTCGTTAACCGG-3′ and 5′-TTAACGACAGG TTCAAAGGACGCAGCT-3′ were used for the MRE nt.

**Luciferase assay**

Cos7 cells were cotransfected with 5 nM miR-92b-3p or control mimic and luciferase reporter constructs using Lipofectamine 2000 (Life technologies). A β-galactosidase expression plasmid was used as an internal transfection control. Twenty-four hours later, luciferase assays were performed, and luciferase activity was presented after normalization to β-galactosidase activity.

**Immunoblotting**

Cells were lysed in TNE buffer (50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 0.1 mM EDTA) and total cell lysates were separated by SDS-PAGE, transferred to PVDF membranes, immunoblotted with antibodies and visualized using an enhanced chemiluminescence detection system (Amersham Biosciences). The antibodies used for immunoblotting were an anti-p70 S6 kinase (49D7), phospho-p70 S6 kinase (Thr389) and TSC1 (D43E2) from Cell signaling. An anti-β-actin antibody (sc47778) was purchased from Santa Cruz.

**Immunofluorescence staining**

Equal amounts of PASMCs were seeded in chamber well slides and then exposed to hypoxia or transfected with control mimic, miR-92b-3p or anti-miR-92b-3p. Cells were fixed in 2% paraformaldehyde, blocked in 3% BSA in PBS and permeabilized in 0.1% Triton X-100 in PBS. The slides were sequentially probed with rabbit anti-human Ki-67 antibody (Abcam, #ab16667) and goat anti-rabbit IgG (H +L) cross-adsorbed secondary antibody, alexa flour 488 (Thermo Fisher Scientific, #A-11008). Nuclei were stained with Hoechst 33342 (Thermo Fisher Scientific, #62249). The slides were imaged by a Zeiss Axio Imager Z1 microscope. At least 2000 cells were counted per condition, and the percentages of Ki-67-positive cells were presented. The results are the mean ± S.E. for triplicate assays.

**TSC1 expression plasmids**

Expression plasmid of TSC1 transcript with deleted 3′-UTR, pcDNA3.1 myc TSC1 (Addgene plasmid # 12133), was a gift from Cheryl Walker [44, 45]. To generate TSC1-expressing vector containing the miR-92b-3p binding site (Control), the pcDNA3.1 myc TSC1 was cleaved by the enzyme AflII. Then, a PCR product including the 3′-UTR sequence (935bp) of TSC1 was ligated into the cleaved pcDNA3.1 myc TSC1 plasmid. 5′-TAACCTTTAGTGTGGAAATGGGACGGA G-3′ and 5′-ATACCTAAAGGCGCTGGAATATGGATGG TCA-3′ were used for the PCR amplification. The TSC1 expression plasmids were transfected into PASMCs using P1 Primary Cell 4D-Nucleofector™ X kit (Lonza) according to the manufacturer’s protocol.

**NGS-based RNA sequencing**

Total RNA was isolated from PASMCs exposed to normoxia or hypoxia for 24 h using Trizol (Invitrogen) according to the manufacturer’s instructions. cDNA libraries were constructed with the TruSeq RNA library kit using 1 μg of total RNA. The protocol consisted of polyA-selected RNA extraction, RNA fragmentation, random hexamer-primed reverse transcription, and 100-n pair-end sequencing by Illumina HiSeq2000. The libraries were quantified using quantitative polymerase chain reaction (qPCR) according to the qPCR quantification protocol guide, and qualified using an Agilent Technologies 2100 Bioanalyzer. To estimate expression levels, the RNA-Seq reads were mapped to the human genome using TopHat [46] and determined using Cufflinks software [47]. The relative transcript abundances were measured in Fragments Per Kilobase of exon per Million fragments mapped (FPKM) using Cufflinks.

To identify altered gene expression levels, transcripts with at least one zeroed FPKM value across all samples were excluded from the analysis. We added 1 to each FPKM value to facilitate log2 transformation. Filtered data were logarithm-transformed and normalized by the quantile method.

**NGS-based small RNA sequencing**

cDNA libraries were constructed with the small RNA library kit using 3 μg of total RNA from PASMCs. To generate a library product, adapter ligation, reverse transcription, PCR amplification, and pooled gel purification were conducted. The RNA 3′-adapter is specifically modified to target miRNAs and other small RNAs that have a 3′-hydroxyl group resulting from enzymatic cleavage by Dicer or other RNA processing enzymes. The adapters are ligated to each end of the RNA molecule and an RT reaction is used to create single stranded cDNA. The cDNA is then PCR amplified using a common primer and a primer containing one of 48 index sequences. The introduction of an index sequence at the PCR step separates the indexes from the RNA ligation reaction. To verify the size of the PCR enriched fragments, the template size distribution was checked by running on an Agilent Technologies 2100 Bioanalyzer using a DNA 1000 chip. The prepared libraries
were quantified using qPCR according to the Illumina qPCR quantification protocol guide. Then, 50-nt single-end sequencing was performed by Illumina HiSeq2000.

After removal of the adaptor sequence in the reads, all reads were clustered to find unique sequences and those were then counted. In order to identify miRNA sequences, the unique sequences found after clustering were searched on the miRBase database by blast. Trimmed reads were considered as miRNA on the condition that they possess 100% sequence identity.

miRNAs with at least one zeroed read count value across all samples were excluded from the analysis. We added 1 to each count value to facilitate log2 transformation. Filtered data were logarithm-transformed and normalized by the TMM method.

**Statistical analysis**

For each of the assays, three experiments were performed in triplicate, and the results were presented as the average with standard error. Statistical analyses were performed by an analysis of variance followed by Student’s t test using Prism 4 software (GraphPAD Software Inc.). P values of < 0.05 were considered significant and are indicated with asterisks.

**Acknowledgements** This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2014R1A1A2057946 and 2016R1D1A1B03932317) to HK.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.
2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Dettre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–23.
3. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675–91.
4. Krymskaya VP, Snow J, Cesareone G, Khavin I, Goncharov DA, Lim PN, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. 2011:25:1922–33.
5. Goncharova EA. mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J. 2013;27:1796–807.
6. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.
7. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.
8. Chan SY, Zhang YY, Hemann M, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10:273–84.
9. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35:856–67.
10. Wu C, So J, Davis-Dusenbery BN, Qi HH, Bloch DB, Shi Y, et al. Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonauta2. Mol Cell Biol. 2011;31:4760–74.
11. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay RE, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J. 2014;35:3203–11.
12. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, et al. Interleukin-6 modulates the expression of the bone morphogenetic protein receptor type II through a novel STAT3-posttranslational modification of Argonaute2. Mol Cell Biol. 2011;31:4760–74.
13. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biol. 2010;7:705–14.
14. Zeng Y, Liu H, Kang K, Wang Z, Hui G, Zhang X, et al. Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci Rep. 2015;5:12098.
15. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biol. 2010;7:705–14.
16. Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F, Chen WY, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J. 2014;35:3203–11.
17. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, et al. Interleukin-6 modulates the expression of the bone morphogenetic protein receptor type II through a novel STAT3-posttranslational modification of Argonaute2. Mol Cell Biol. 2011;31:4760–74.
18. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biol. 2010;7:705–14.
19. Zeng Y, Liu H, Kang K, Wang Z, Hui G, Zhang X, et al. Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci Rep. 2015;5:12098.
20. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biol. 2010;7:705–14.
21. Zeng Y, Liu H, Kang K, Wang Z, Hui G, Zhang X, et al. Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci Rep. 2015;5:12098.
22. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF. RNA Biol. 2010;7:705–14.
23. Zeng Y, Liu H, Kang K, Wang Z, Hui G, Zhang X, et al. Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci Rep. 2015;5:12098.
miR-92b-TSC1 axis is critical for mTOR signaling-mediated vascular smooth muscle cell proliferation.

20. Loscalzo J. The cellular response to hypoxia: tuning the system with microRNAs. J Clin Invest. 2010;120:3815–7.

21. Nallamsetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol & Med. 2013;64:20–30.

22. Jin Y, Pang T, Nelín LD, Wang W, Wang Y, Yan J, et al. MKP-1 is a target of miR-210 and mediates the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation. Cell Biol Int. 2015;39:113–20.

23. Sommer N, Dietrich A, Schermuly RT, Ghofrani HA, Gudermann T, Schulz R, et al. Regulation of hypoxia pulmonary vasoconstriction: basic mechanisms. Eur Respir J. 2008;32:1639–51.

24. Wu ZB, Cai L, Lin SJ, Lu JL, Yao Y, Zhou LF. The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. Brain Res. 2013;1529:16–25.

25. Zhou Z, Wang Z, Wei H, Wu S, Wang X, Xiao J. Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma. Clin Sci. 2016;130:921–30.

26. Sengupta S, Nie J, Wagner RJ, Yang WY, Disney MD, Sengupta S, Nie J, Wagner RJ, Yang WY, Disney MD, et al. Downregulation of miR-144 is associated with colorectal carcinoma cells via targeting of mTOR. Biotechnol Lett. 2016;38:409–16.

27. Huang J, Wang B, Hui K, Zeng J, Fan J, Wang X, et al. miR-92b-3p-TSC1 axis is critical for mTOR signaling-mediated vascular smooth muscle cell proliferation. Cancerogene. 2012;33:2391–7.

28. Liu P, Wilson MJ. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-kappaB factor in human fibrosarcoma cells. J Cell Physiol. 2012;227:867–76.

29. Onyema C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene. 2011;30:3489–501.

30. Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol. 2013;30:411.

31. Wang L, Chang L, Li Z, Gao Q, Cai D, Tian Y, et al. miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. Med Oncol. 2014;31:934.

32. Zhang Y, Li CF, Ma LJ, Ding M, Zhang B. MicroRNA-224 aggravates tumor growth and progression by targeting mTOR in gastric cancer. Int J Oncol. 2016;49:1068–80.

33. Chen HH, Huang WT, Yang LW, Lin CW. The PTEN-AKT-mTOR/RICTOR pathway in nasal natural killer cell lymphoma is activated by miR-494-3p via PTEN but inhibited by miR-142-3p via RICTOR. Am J Pathol. 2015;185:1487–99.

34. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78.

35. Cho JR, Lee CY, Lee J, Seo HH, Choi E, Chung N, et al. MicroRNA-761 inhibits Angiotsensin II-induced vascular smooth muscle cell proliferation and migration by targeting mammalian target of rapamycin. Clin Hemorheol Microcirc. 2015;63:45–56.

36. Grundmann S, Hans FP, Kinniry S, Heinke J, Helbing T, Bluhm F, et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation. 2011;123:999–1009.

37. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006;173:279–91.

38. Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS ONE. 2014;9:e92099.

39. Huo F, Zhang C, He H, Wang Y. MicroRNA-144-3p inhibits proliferation and induces apoptosis of human salivary adenoid carcinoma cells via targeting of mTOR. Biotechnol Lett. 2016;38:1009–16.

40. Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012;33:2391–7.